FDA: PPIs and Clostridium Difficile

Published Online: Friday, July 20, 2012
Follow Pharmacy_Times:
In this podcast, Steve Jackson, a pharmacist in the FDA’s division of drug information, warns that use of proton pump inhibitors (PPIs) may be associated with an increased risk of Clostridium difficile–associated diarrhea.
 
To listen to the podcast, click here.
Related Articles
The FDA today approved Ivax Pharmaceuticals’ esomeprazole magnesium delayed-release capsules, the first generic version of AstraZeneca’s proton pump inhibitor Nexium, for the treatment of gastroesophageal reflux disease in patients aged >1 year.
Treating traveler’s diarrhea with antibiotics may contribute to antibiotic resistance and spread resistant bacteria strains, particularly if travelers visit developing parts of the world.
J. Russell May, PharmD, FASHP, clinical professor at Georgia Regents University College of Pharmacy, discusses how new agents are helping address Clostridium difficile-associated diarrhea concerns.
A recent review of inappropriate prescribing among hospitalized older adults revealed that proton pump inhibitors follow only opiates and benzodiazepines as the most frequently misprescribed medications.
Latest Issues
  • photo
    Pharmacy Times
    photo
    Health-System Edition
    photo
    Directions in Pharmacy
    photo
    OTC Guide
    photo
    Generic Supplements
  • photo
    Pharmacy Careers
    photo
    Specialty Pharmacy Times
    photo
    Generic
$auto_registration$